TP与EC-T新辅助化疗方案治疗三阴性乳腺癌的pCR率及不良反应比较

目的比较TP(紫杉醇+卡铂)与EC-T(表柔比星+环磷酰胺序贯紫杉醇)新辅助化疗(NAC)方案治疗三阴性乳腺癌(TNBC)的病理学完全缓解(pCR)率及临床不良反应。方法回顾性分析我院收治的126例TNBC患者的临床资料,应用TP方案的患者为观察组(n=65),应用EC-T方案的患者为对照组(n=61)。观察组与对照组均行8周期化疗,术后评估pCR率及临床不良反应发生情况。结果观察组的pCR率为33.85%,高于对照组的16.39%(P<0.05)。两组患者的各项不良反应发生率比较,差异均无统计学意义(P>0.05)。结论TNBC患者术前NAC应用TP方案治疗,pCR率明显优于EC-T方案,不良反应发生率无明显增加,值得临床应用。

Comparison of the pCR rate and adverse reactions of TP and EC-T neoadjuvant chemotherapy in the treatment of triple negative breast cancer

Objective To compare the pathological complete response(pCR)rate and clinical adverse reactions of TP(paclitaxel+carboplatin)and EC-T(epirubicin+cyclophosphamide sequential paclitaxel)neoadjuvant chemotherapy(NAC)in the treatment of triple negative breast cancer(TNBC).Methods The clinical data of 126 patients with TNBC treated in our hospital were retrospectively analyzed.The patients given TP were set as observation group(n=65),and the patients given EC-T were set as control group(n=61).The observation group and the control group were treated with 8 cycles of chemotherapy,and the pCR rate and the incidence of clinical adverse reactions were evaluated postoperatively.Results The pCR rate of the observation group was 33.85%,which was higher than 16.39%of the control group(P<0.05).There were no significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion Preoperative NAC with TP regimen in the treatment of TNBC patients can get better pCR rate compared with EC-T regimen,without significant increase of the incidence of adverse reactions,which is worthy of clinical application.